GET DAILY SIGNALSMineralys Therapeutics (MLYS) Stock Falls -25.5% Over the Past 30 Days
Key Takeaways
- Mineralys Therapeutics (MLYS) shares have fallen roughly 25.5% over the last 30 days, sliding from a closing price of $25.13 on September 30, 2026, to around $18.72.
- The decline extends a broader retreat, with the stock down approximately 28% over the trailing three months.
- Mineralys remains a pre-revenue, single-asset biotech, and its Q2 2026 net loss widened to $241.1 million, partly reflecting a one-time $200 million royalty repurchase.
- Positive lorundrostat data presented at two major medical meetings during the period did not reverse the selling pressure.
- A $150 million equity offering and competitive concerns around AstraZeneca's (AZN) baxdrostat weighed on investor sentiment.
- The primary upcoming catalyst is the FDA's December 22, 2026 PDUFA target action date for lorundrostat.
Company Background for Mineralys Therapeutics (MLYS)
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on treating hypertension and related cardiorenal conditions. Its lead candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed to reduce aldosterone production by inhibiting the CYP11B2 enzyme. The company is pursuing approval in uncontrolled and resistant hypertension, with additional development efforts in chronic kidney disease and obstructive sleep apnea. Lorundrostat's pivotal Launch-HTN trial demonstrated placebo-adjusted systolic blood pressure reductions of 9.1 mmHg at week six and 11.7 mmHg at week 12. Mineralys targets a large addressable population of roughly 20 million U.S. adults with uncontrolled or resistant hypertension, a group in which less than half of patients reach their blood pressure goals with existing therapies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance for MLYS
Over the last 30 days, MLYS has declined approximately 25.5%, from a September 30, 2026, close of $25.13 to around $18.72. The decline has been broadly consistent rather than concentrated in a single event, with the stock drifting lower through October despite intermittent data-driven bounces. Over the trailing quarter, the pullback is even steeper: from a level near $26.19 in late July 2026, shares have lost roughly 28% of their value. Notably, the stock had briefly traded near $31 in early September before giving back those gains, reflecting a period of elevated volatility around clinical and regulatory milestones.
Factors Influencing the 30-Day Move
The 30-day slide occurred even as Mineralys delivered positive clinical updates. On October 9, 2026, the company presented a new Launch-HTN analysis at the American Heart Association Hypertension Scientific Sessions showing that 46% of lorundrostat-treated participants reached the guideline-recommended systolic blood pressure target of less than 130 mmHg at week 12. Later in October, additional Launch-HTN analyses presented at ASN Kidney Week showed consistent blood pressure reductions in patients with chronic kidney disease and a 52% placebo-adjusted reduction in albuminuria among albuminuric participants.
Despite these data, the shares moved lower. Several factors appear to have outweighed the positive readouts. As a pre-revenue company, Mineralys continues to post substantial operating losses, and its Q2 2026 results revealed a net loss of $241.1 million driven in part by a one-time $200 million royalty repurchase. The company also completed a $150 million equity offering, introducing dilution. Competitive dynamics added further pressure, as investors weighed the potential commercial entry of AstraZeneca's (AZN) baxdrostat, another aldosterone synthase inhibitor, ahead of lorundrostat's approval. Broader risk-off sentiment across the biotechnology sector also contributed to the downward trend.
Quarterly Trends and Broader Context
The quarterly decline reflects a longer-running repricing of a single-asset, pre-revenue company ahead of a binary regulatory decision. Following a run-up into early September, the stock has steadily trended lower as investors weighed financing needs, competitive positioning, and execution risk. The second-quarter report, released in August 2026, highlighted sharply higher expenses tied to commercial launch preparation and the royalty repurchase, alongside a financing package that included the $150 million equity raise and a $500 million senior secured term loan. While management reiterated a cash runway into 2028 and emphasized payer and key-opinion-leader engagement, the market has remained cautious about dilution and the company's dependence on a single product through the FDA review cycle.
Looking Ahead for MLYS Investors
The most important near-term catalyst is the FDA's decision on lorundrostat, with a PDUFA target action date of December 22, 2026. Investors will also monitor label and post-approval discussions, commercial launch preparations, and the company's ability to secure broad payer access. Competitive developments, including the commercial trajectory of AstraZeneca's baxdrostat, could shape the aldosterone synthase inhibitor market. Financial considerations remain relevant as well, including cash burn, the sufficiency of the runway into 2028, and any future financing activity. Further data presentations across chronic kidney disease and other indications could also influence the longer-term narrative. As with any clinical-stage biopharmaceutical company, regulatory outcomes and execution risk remain key variables. From what I see, this is important because the outcome could define the company's path forward.
Exploring AI Tools in My Research Process
I've found Tickeron's AI Trading Bots useful for reviewing automated strategies that cover a wide range of tickers and timeframes. It lets me compare different approaches and see how they align with current market conditions without needing to build everything from scratch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MLYS in +3.99% Uptrend, growing for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MLYS advanced for three days, in 169 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MLYS's RSI Indicator exited the oversold zone, 18 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 51 cases where MLYS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for MLYS just turned positive on October 22, 2026. Looking at past instances where MLYS's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
MLYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLYS as a result. In 51 of 60 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 10-day moving average for MLYS crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MLYS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.408) is normal, around the industry mean (3.070). P/E Ratio (-5.057) is within average values for comparable stocks, (-1.257). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. MLYS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLYS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement